Logo

MISSION

CarthroniX is a clinical-stage biotechnology company developing next-generation therapies to combat the effects of age-related inflammation. 
We have identified a key linkage between inflammation and cellular aging, and our proprietary patented platform is designed to reverse this process. By targeting the fundamental drivers of age-related disease, our mission is to establish a new standard of care, unlocking a multi-billion dollar market opportunity and delivering significant returns to our partners and investors.

OUR TEAM

Hassan Serhan, Ph.D.

CEO/Board Member
Dr. Hassan Serhan, CEO of CarthroniX, is a seasoned healthcare leader with deep expertise in technology innovation, product development, and leading large-scale global programs. He held senior leadership roles and served as a Distinguished Fellow at Johnson & Johnson’s DePuy Synthes, where he cultivated influential relationships across the medical and scientific community. A passionate advocate for advancing care worldwide, he co-founded the International Musculoskeletal Society and actively participates in medical missions. Dr. Serhan also advises multiple medtech companies, serves on their boards, and is a Prestige Adjunct Professor at the University of Toledo.
Hassan Serhan, Ph.D.
Ben Van Handel, Ph.D.

Ben Van Handel, Ph.D.

Chief Scientific Officer/Co-Founder/Board Member
Dr. Ben Van Handel is an accomplished stem cell scientist and entrepreneur with a proven track record of bringing innovative therapies to market. As the co-founder of Carthronix, he recently led the company to a key milestone: the FDA clearance of the CX-011 osteoarthritis IND, advancing its lead therapeutic program into clinical trials. An award-winning researcher, Dr. Van Handel has authored over 60 papers on regenerative medicine and stem cell biology, which have been cited more than 5,000 times. He holds a B.S. in Biochemistry from Northern Michigan University and a Ph.D. in Molecular, Cell, and Developmental Biology from UCLA. Dr. Van Handel has also founded three companies, serving as CEO for each, and has successfully raised significant capital.

Irina Evseenko

Board Member
Mrs. Irina Evseenko is a seasoned professional with over 20 years of international experience in nonprofit and business development. She has Master in Management and Employment Relations and a postgraduate diploma in Human Resources Management from the University of California Los Angeles (UCLA). Irina is a strong leader, successful entrepreneur, and environmental advocate. She oversees CarthroniX operations and works on developing first-in-class true stem cell luxury cosmetic line Heraux.
Irina  Evseenko
Gregory Sieczkiewicz, Ph.D, J.D.

Gregory Sieczkiewicz, Ph.D, J.D.

Chief IP Counsel
Greg has extensive experience working with venture capital firms, venture-backed life sciences startups, and public biotechnology companies.  Greg is also Chief IP Counsel at MPM Capital. He has served as Vice President, IP at Flagship Ventures, and also practiced patent prosecution and enforcement at national law firms Mintz Levin, Proskauer Rose and Foley Hoag. Greg is a member of the bar of the Commonwealth of Massachusetts and is admitted to practice before the U.S. Patent and Trademark Office. He is also the former President of the Boston Patent Law Association.

R. Rex Parris

Founding Investor/Attorney
Mr. R. Rex Parris Esq. is the founder of Parris Law and the Mayor of Lancaster, California.  Lancaster became the first net zero mid-size city in the world under his leadership.  He formed public/private partnerships with green energy companies and is successfully converting all of the city’s energy needs to green energy.  He recently was named the Green Power Leader of the nation by the United States Environmental Protection Agency. He now is directing his energies to help eliminate inflammatory disease.  Mr. Parris approach to solutions is a simple approach:  “Find the smartest people in the field who work tirelessly.  Then get them the funding to do their work. My job is to deal with the bureaucratic obstacles.  It worked with putting a dent in climate extinction, and it will work with eliminating inflammatory disease.”
R. Rex Parris

ADVISORY BOARD

Frank Petrigliano, M.D.

Dr. Frank Petrigliano is a orthopaedic sports medicine surgeon in Los Angeles and Vice Chair of Education for the UCLA Department of Orthopadic Surgery. Dr. Petrigliano serves as the head team physician for the LA Chargers Football team and an associate team physician for UCLA Athletics. He specializes in the care of athletic injuries of the shoulder, knee, and elbow. A native of New York, Dr. Petrigliano completed his undergraduate training at Cornell University where he graduated with honors. Dr. Petrigliano then attended the Rutgers Robert Wood Johnson Medical School for his medical training and his residency in Orthopaedic Surgery at UCLA.  After residency, Dr. Petrigliano completed a fellowship in Sports Medicine and Shoulder Surgery at the prestigious Hospital for Special Surgery and Weill Cornell Medical College in New York City where he assisted in the care of the Brooklyn Nets and Iona College Athletics. Prior to returning to UCLA, Dr. Petrigliano served as chief of the Epstein Family Center for Sports Medicine at Keck Medicine of USC and head team physician for the LA Kings hockey team.
Frank Petrigliano, M.D.
Ali Guermazi, M.D., Ph.D., M.Sc.

Ali Guermazi, M.D., Ph.D., M.Sc.

Ali Guermazi, MD, PhD, MSc is a Professor of Radiology and Medicine, Director of the Quantitative Imaging Center, and Assistant Dean of Diversity and Inclusion at Boston University School of Medicine. He is the Chief of Radiology at the VA Boston Healthcare System. Prof. Guermazi has been involved as an MRI reader for the past 25 years in several large U.S. studies including the Health Aging and Body Composition (Health ABC) study, the Boston Osteoarthritis Knee study (BOKS), the Multi-center Osteoarthritis STudy (MOST), the Framingham study, Osteoarthritis Initiative (OAI), and other large NIH-funded studies, as well as several Pharmaceutical-sponsored clinical trials.

Denis A. Evseenko, MD, Ph.D.

Dr. Evseenko is a pioneer in stem cell biology, regenerative medicine and pharmacology; He has made significant fundamental contributions to the area of musculoskeletal biology and disease; Dr. Evseenko has invented several novel prospective cell-based and small-molecule-based therapies for arthritis and articular cartilage regeneration. He is the author of numerous peer-reviewed research articles, presentations and patents.
Denis A. Evseenko, MD, Ph.D.
Mark G. Rubin, M.D.

Mark G. Rubin, M.D.

A Beverly Hills Board Certified Dermatologist, Dr. Rubin is an expert in innovative therapies and personalized care for conditions of the skin, with a particular interest in skin rejuvenation. He has been in practice for more than 20 years. Dr. Rubin has written multiple papers, book chapters, and a textbook on skin rejuvenation. He has also personally trained over 600 physicians in his technique of skin rejuvenation. He is an international lecturer and has presented his ideas and research in over ten countries. In addition to his work with patients, Dr. Rubin also performs clinical research projects and works as a consultant for various skincare and medical device companies.